Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
3.890
-0.010 (-0.26%)
At close: Oct 21, 2025, 4:00 PM EDT
3.530
-0.360 (-9.25%)
After-hours: Oct 21, 2025, 4:50 PM EDT
Orchestra BioMed Holdings Employees
Orchestra BioMed Holdings had 70 employees as of December 31, 2024. The number of employees increased by 14 or 25.00% compared to the previous year.
Employees
70
Change (1Y)
14
Growth (1Y)
25.00%
Revenue / Employee
$42,057
Profits / Employee
-$995,700
Market Cap
209.89M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 70 | 14 | 25.00% |
| Dec 31, 2023 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OBIO News
- 12 days ago - Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit - GlobeNewsWire
- 6 weeks ago - Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout - GlobeNewsWire
- 2 months ago - Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology - GlobeNewsWire
- 2 months ago - Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction - GlobeNewsWire
- 2 months ago - Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - GlobeNewsWire
- 2 months ago - Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility - GlobeNewsWire
- 2 months ago - Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings - GlobeNewsWire
- 2 months ago - Orchestra BioMed Announces Pricing of $40 Million Public Offering - GlobeNewsWire